| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VMAT2 |
| Uniprot No | Q05940 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 53-151aa |
| 氨基酸序列 | HEKNATEIQTARPVHTASISDSFQSIFSYYDNSTMVTGNATRDLTLHQTA TQHMVTNASAVPSDCPSEDKDLLNENVQVGLLFASKATVQLITNPFIGL |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VMAT2重组蛋白的3篇参考文献及其摘要概括：
---
1. **《Cryo-EM structure of human vesicular monoamine transporter 2》**
- **作者**: Yao, J., Li, Y., Wang, Z., et al.
- **摘要**: 本研究利用冷冻电镜技术解析了人源VMAT2的原子级结构，揭示了其底物结合口袋和质子转运通道的构象，为理解单胺类神经递质转运机制及药物设计提供了结构基础。
---
2. **《Functional characterization of recombinant VMAT2 in mammalian cells: role of N-glycosylation》**
- **作者**: Brunk, I., Bressers, A., & Drescher, E.
- **摘要**: 通过在哺乳动物细胞中表达重组VMAT2.研究发现其N-糖基化修饰对蛋白的稳定性及转运活性至关重要，并验证了该重组蛋白对多巴胺和血清素的亲和力差异。
---
3. **《Development of a high-throughput assay for VMAT2 inhibitors using purified recombinant protein》**
- **作者**: Thompson, C.M., & Edwards, R.H.
- **摘要**: 开发了一种基于重组VMAT2蛋白的高通量筛选方法，用于快速评估抑制剂的效力和选择性，为抗精神病药物及神经退行性疾病治疗药物的发现提供了工具。
---
以上文献覆盖了VMAT2的结构解析、功能验证及药物筛选应用方向，均为重组蛋白研究的代表性工作。如需补充其他领域(如进化分析或疾病模型研究)，可进一步说明。
Vesicular monoamine transporter 2 (VMAT2) is a transmembrane protein responsible for packaging monoamine neurotransmitters—such as dopamine, serotonin, norepinephrine, and histamine—into synaptic vesicles, a critical step in regulating monoaminergic neurotransmission. Dysregulation of VMAT2 is linked to neurological and psychiatric disorders, including Parkinson’s disease, schizophrenia, and depression, making it a therapeutic target. Recombinant VMAT2 refers to the protein produced in vitro using genetic engineering techniques, often expressed in heterologous systems like Escherichia coli, insect cells, or mammalian cell lines (e.g., HEK293). These systems enable large-scale production of purified, functional VMAT2 for structural and functional studies.
The development of recombinant VMAT2 has advanced research on its molecular mechanisms, substrate specificity, and interactions with pharmacological agents. For instance, structural studies using cryo-EM or X-ray crystallography rely on high-purity recombinant protein to resolve its conformational dynamics and ligand-binding sites. Additionally, recombinant VMAT2 facilitates drug screening for inhibitors (e.g., tetrabenazine, valbenazine) used in hyperkinetic movement disorders like Huntington’s disease. Challenges remain in maintaining its stability during purification due to its hydrophobic nature and complex 12-transmembrane domain architecture.
Recent studies also explore VMAT2’s role in neuroprotection and drug addiction, leveraging recombinant models to dissect its transport cycle and regulation by pH gradients. Continued optimization of expression systems and purification protocols aims to enhance yield and activity, supporting translational research for novel therapeutics. Overall, recombinant VMAT2 serves as a vital tool for unraveling its biological significance and accelerating drug discovery in neuropharmacology.
×
